Funding for this research was provided by:
Camurus Lipid Research Foundation (N/A)
Pilgrim Trust (N/A)
Text and Data Mining valid from 2019-04-03
Received: 1 January 2019
Accepted: 22 March 2019
First Online: 3 April 2019
Ethics approval and consent to participate
: This study received approval from the Psychiatry, Nursing and Midwifery Research Ethics Subcommitttee (PNM RESC), King’s College London (HR-17/18-5957).
: Not applicable.
: Joanne Neale has received honoraria and research grants from pharmaceutical companies: Camurus AB and Mundipharma International Ltd. John Strang is a researcher and clinician who has worked with a range of types of treatment and rehabilitation service-providers. He has also worked with a range of governmental and non-governmental organizations, and with pharmaceutical companies to seek to identify new or improved treatments from whom he and his employer (King’s College London) have received honoraria, travel costs, and/or consultancy payments. This has included discussions with Camurus AB, Indivior and Molteni Farma (all three of whom have developed ultra-long-acting buprenorphine formulations) and also an oversight role for the UK part of a safety trial of CAM2038/Buvidal®, the product discussed in this paper. For a fuller account, see John Strang’s web-page at: ExternalRef removed. Charlotte Tompkins received salary support from Camurus AB whilst undertaking this study.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.